- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00344188
Diagnose og behandling av Leishmania-infeksjoner
Vertsrespons på infeksjon og behandling ved Leishmania-infeksjon hos mennesker
Patients admitted on this protocol must have an active Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural history of the treated infection and further understand host and species characteristics that lead to resistant or relapsing disease. As part of the standard evaluation of these patients, biopsies to obtain parasite and host tissue will be obtained. The host response before and after therapy will be assessed to address broader questions related to diagnosis, disease pathogenesis, and response to therapy. Careful observations of the patients clinical and immunologic responses to therapy will be made, as well as long-term follow-up of these changes. It is anticipated that the patients will receive optimal clinical care for their infections and that the specimens collected from them will prove to be valuable reagents for the laboratory studies of the host responses unique to leishmanial infections.
Based on the nature of the disease and the recommended treatment, subjects will receive clinically appropriate treatment. Patients will undergo a limited physical examination to assess general condition, respiratory status, and skin condition. Following treatment patients are seen at 3 months and 12 months. Blood, lesion swabs, mucosal swabs, microbiopsies and/or skin biopsies will be collected for research evaluations. There will also be a mandatory check in (photos, telephone or telehealth visit) at 6 months. All of these post treatment timepoints are used to follow the course of the disease and management. Additional visits may be scheduled for clinically indicated procedures as guided by clinical status and need for evaluation. Samples collected from clinical evaluations may also be studied for research purposes and the results will be collected as part of this protocol. Participants enrolled can be assessed using an approved virtual platform. Study visits can be performed remotely if outside physicians are able to submit study specimens (blood samples, lesion and mucosal swabs).
The final study visit will typically be at 1 year following successful treatment. Blood will be collected, and swabs/microbiopsies may be collected for research evaluations at this visit. Follow up visits beyond the 1-year post-treatment point may occur on an annual basis if clinically necessary, as deemed by the investigator.
Studieoversikt
Status
Detaljert beskrivelse
Patients admitted on this protocol will have, or be suspected of having, a Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural history of the treated infection and further understand host and species characteristics that lead to resistant or relapsing disease. As part of the standard evaluation of these patients, biopsies to obtain parasite and host tissue will be obtained. The host response before and after therapy will be assessed to address broader questions related to diagnosis, disease pathogenesis, and response to therapy. Careful observations of the patients clinical and immunologic responses to therapy will be made, as well as long-term follow-up of these changes. It is anticipated that the patients will receive optimal clinical care for their infections and that the specimens collected from them will prove to be valuable reagents for the laboratory studies of the host responses unique to leishmanial infections.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Elise M O'Connell, M.D.
- Telefonnummer: (301) 761-5413
- E-post: oconnellem@mail.nih.gov
Studiesteder
-
-
Maryland
-
Bethesda, Maryland, Forente stater, 20892
- Rekruttering
- National Institutes of Health Clinical Center
-
Ta kontakt med:
- Lori Penrod
- Telefonnummer: 240-627-3647
- E-post: lpenrod@niaid.nih.gov
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
This population of patients are referred from their physicians both regionally and nationally.
Beskrivelse
- INCLUSION CRITERIA:
- Individuals aged 3 to 100 years.
- Diagnosis of leishmaniasis:
A: Biopsy proven
OR
B: Likely diagnosis of leishmaniasis based on :
Epidemiologic exposure, clinical manifestations, and time course
- Willingness to allow samples to be stored for future research.
- Ability to provide informed consent.
EXCLUSION CRITERIA:
Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
1
This population of patients are referred from their physicians both regionally and nationally. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Obtain a basic immune workup and biobank PBMCs, plasma, and cultured leishmania isolates
Tidsramme: 1 year
|
Obtain a basic immune workup and host genetic information (WGS) |
1 year
|
|
Obtain organism genomic data at the initial time of NIH presentation and any further relapses
Tidsramme: 1 year
|
Obtain organism genomic data at the initial time of NIH presentation and any further relapses |
1 year
|
|
Obtain phenotypic and clinical information to document refractory and relapsing clinical courses.
Tidsramme: 1 year
|
Obtain phenotypic and clinical information to document refractory and relapsing clinical courses. |
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Determine if sequential quantitative qPCR for leishmania spp. from lesion(s) obtained by microbiopsy (nodular disease) or swabbing (ulcerative disease) correlates with healing
Tidsramme: 1 year
|
Examine biomarkers as predictors of clinical course |
1 year
|
|
Assess the safety profile of varying treatment regimens
Tidsramme: 1 year
|
Assess the safety profile of varying treatment regimens |
1 year
|
|
Assess the efficacy of varying treatment regimens in different species
Tidsramme: 1 year
|
Assess the efficacy of varying treatment regimens in different species |
1 year
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Elise M O'Connell, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 010238
- 01-I-0238
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
No.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .